X70 Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Panbela Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.01 |
| 52 Week High | US$70.00 |
| 52 Week Low | US$1.76 |
| Beta | 0.92 |
| 11 Month Change | 0% |
| 3 Month Change | -0.017% |
| 1 Year Change | -95.77% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| X70 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | 0.9% |
| 1Y | -95.8% | -16.6% | 3.0% |
Return vs Industry: X70 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: X70 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| X70 volatility | |
|---|---|
| X70 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: X70's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine X70's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 7 | Jennifer Simpson | www.panbela.com |
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with cancer. The company’s lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101).
Panbela Therapeutics, Inc. Fundamentals Summary
| X70 fundamental statistics | |
|---|---|
| Market cap | €7.54m |
| Earnings (TTM) | -€31.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs X70 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X70 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$34.93m |
| Earnings | -US$34.93m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -85.0% |
How did X70 perform over the long term?
See historical performance and comparison